Previous studies, including our own, have shown that acquired gemcitabine resistance upregulates IL-8 expression [31,32,33], which enhances the angiogenic and invasive capabilities of pancreatic cancer cells. This evidence concerns the gene CXCL8 and familial pancreatic carcinoma.